FORM 10-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT TO APPLICATION OR REPORT
Filed pursuant to Section 12, 13, or 15(d) of THE SECURITIES
EXCHANGE ACT OF 1934
DEKALB Genetics Corporation
(Exact name of registrant as specified in charter)
AMENDMENT NO. 1
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its Annual Report for 1993 on Form
10-K as set forth in the pages attached hereto:
Exhibit 28 - Additional Exhibit
Form 11-K
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf by the
undersigned, thereunto duly authorized.
DEKALB Genetics Corporation
(Registrant)
By:
Bruce P. Bickner
Chairman and Chief Executive
Officer
Date: January 3, 1994
<PAGE>
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 11-K
(Mark One)
X Annual Report Pursuant to Section 15(d) of the
Securities Exchange Act of 1934 (Fee Required)
For the fiscal year ended August 31, 1993
OR
Transition Report Pursuant to Section 15(d) of the
Securities Exchange Act of 1934 (No Fee Required)
For the transition period from to
Commission file number 33-33305
DEKALB Genetics Corporation Savings and Investment Plan
(Full title of the plan)
DEKALB GENETICS CORPORATION
3100 Sycamore Road
DeKalb, Illinois 60115
(Name of Issuer of the securities held pursuant to the plan
and address of its principal executive office.)
<PAGE>
<PAGE>
DEKALB Genetics Corporation
Savings and Investment Plan
Report of Audits of Financial Statements
and Supplemental Schedules
For the years ended August 31, 1993 and 1992
<PAGE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
INDEX TO FINANCIAL STATEMENTS
Page(s)
Report of Independent Accountants 2
Financial Statements:
Statement of Net Assets Available for
Plan Benefits as of August 31, 1993 3
Statement of Net Assets Available for
Plan Benefits as of August 31, 1992 4
Statements of Changes in Net Assets Available
for Plan Benefits for the years ended
August 31, 1993 and 1992 5
Notes to Financial Statements 6 - 10
Supplemental Schedules:
Item 27a - Schedule of Assets Held for Investment
Purposes at August 31, 1993 11 - 12
Item 27d - Schedule of Reportable Transactions
for the year ended August 31, 1993 13
Notes: Supplemental schedules required by the Employee Retirement Income
Security Act that have not been included herein are not applicable to
the DEKALB Genetics Corporation Savings and Investment Plan.
<PAGE>
<PAGE>
<AUDIT-REPORT>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Administrative Committee
DEKALB Genetics Corporation Savings
and Investment Plan
We have audited the statements of net assets available for plan benefits of
the DEKALB Genetics Corporation Savings and Investment Plan (the "Plan") as of
August 31, 1993 and 1992, and the related statements of changes in net assets
available for plan benefits for the years then ended. These financial
statements are the responsibility of the Plan's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the net assets of the Plan as of August 31, 1993 and
1992, and changes in net assets available for plan benefits for the years then
ended in conformity with generally accepted accounting principles.
Our audits were conducted for the purpose of forming an opinion on the basic
financial statements taken as a whole. The supplemental schedules, as listed
in the accompanying index on page 1, are presented for the purpose of
additional analysis and are not a required part of the basic financial
statements but are supplementary information required by the Department of
Labor's Rules and Regulations for Reporting and Disclosure under the Employee
Retirement Income Security Act of 1974. The supplemental schedules have been
subjected to the auditing procedures applied in the audits of the basic
financial statements and, in our opinion, are fairly stated, in all material
respects, in relation to the basic financial statements taken as a whole.
COOPERS & LYBRAND
Chicago, Illinois
December 1, 1993
</AUDIT-REPORT>
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings and Investment Plan
Statement of Net Assets Available for Plan Benefits
as of August 31, 1992
MONEY FIXED CAPITAL COMPANY PFIZER
EQUITY MARKET INCOME PRESERVATION STOCK STOCK PARTICIPANT
ASSETS FUND FUND FUND FUND FUND FUND LOAN FUND TOTAL
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Investments, at fair market value:
Company common stock $757,988 $757,988
Common stocks $35,917,478 65,817 35,983,295
Corporate bond and
bond investment funds 3,276,734 3,276,734
U.S. Treasury bonds and notes 13,052,572 13,052,572
Collective short-term
investment fund 1,746,727 11,460,784 147,080 2,718 13,357,309
Guaranteed investment account 18,953,044 18,953,044
Participant loans 1,184,790 1,184,790
Total Investments 37,664,205 11,460,784 16,476,386 18,953,044 757,988 68,535 1,184,790 86,565,732
Receivables:
Company contribution 61,122 18,145 19,126 9,262 9,005 116,660
Accrued interest and div 90,760 35,680 159,361 94 5,352 323 291,570
151,882 53,825 178,487 9,356 14,357 323 408,230
Total Assets 37,816,087 11,514,609 16,654,873 18,962,400 772,345 68,858 1,184,790 86,973,962
LIABILITIES
Payable to termin 304,463 99,777 122,513 595,954 16,391 1,139,098
Other liabilities 18,899 6,426 8,494 6,774 7,430 48,023
Total Liabilities 323,362 106,203 131,007 602,728 23,821 1,187,121
NET ASSETS AVAILABLE
FOR PLAN BENEFITS $37,492,725 $11,408,406 $16,523,866 $18,359,672 $748,524 $68,858 $1,184,790 $85,786,841
<FN>
The accompanying notes are an integral part of these financial statements.
</TABLE>
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings and Investment Plan
Statement of Net Assets Available for Plan Benefits
as of August 31, 1993
MONEY FIXED CAPITAL COMPANY PFIZER
EQUITY MARKET INCOME PRESERVATION STOCK STOCK PARTICIPANT
ASSETS FUND FUND FUND FUND FUND FUND LOAN FUND TOTAL
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Company common stock $923,111 $923,111
Common stocks $42,786,789 53,676 42,840,465
Corporate bond and
bond investment funds 7,015,421 1,292,904 8,308,325
U.S. Treasury bonds and notes 12,520,128 12,520,128
Collective short-term
investment fund 1,352,211 10,532,700 335,669 531,117 4,178 105 12,755,980
Guaranteed investment ac - 17,727,605 17,727,605
Participant loans - 1,255,046 1,255,046
Total Investments 44,139,000 10,532,700 19,871,218 19,551,626 923,111 57,854 1,255,151 96,330,660
Receivables:
Company Contributions 1,531 6,506 1 1 (620) 18,600 26,019
Accrued interest and div 103,084 28,632 136,278 1,239 7,536 370 5,410 282,549
104,615 35,138 136,279 1,240 6,916 370 24,010 308,568
Total Assets 44,243,615 10,567,838 20,007,497 19,552,866 930,027 58,224 1,279,161 96,639,228
LIABILITIES
Other liabilities 15,767 7,202 6,604 6,408 5,054 8,032 49,067
Total Liabilities 15,767 7,202 6,604 6,408 5,054 8,032 49,067
NET ASSETS AVAILABLE
FOR PLAN BENEFITS $44,227,848 $10,560,636 $20,000,893 $19,546,458 $924,973 $58,224 $1,271,129 $96,590,161
<FN>
The accompanying notes are an integral part of these financial statements.
</TABLE>
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings and Investment Plan
Statement of Changes in Net Assets Available for Plan Benefits
for the years ended August 31, 1993 and 1992
MONEY FIXED CAPITAL COMPANY PFIZER
EQUITY MARKET INCOME PRESERVATION STOCK STOCK PARTICIPANT
FUND FUND FUND FUND FUND FUND LOAN FUND TOTAL
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at August 31, $32,023,862 $12,552,523 $12,649,254 $20,516,576 $573,536 $57,524 $78,373,275
Participant loan balance at
Sept. 1, 1991 (Note 2) 1,070,974 1,070,974
Contributions:
Company 622,014 204,461 218,301 202,644 114,648 1,362,068
Participant 1,586,071 600,430 652,015 392,899 274,696 3,506,111
Interest income 406,941 562,511 1,074,236 1,472,593 96 85,708 3,602,085
Dividend income 678,369 18,894 1,227 698,490
Net appreciation (depreciation)
in fair value of in 2,055,540 770,161 (112,986) 10,011 2,722,726
Distributions (1,485,526) (1,540,677) (551,258) (1,475,186) (40,509) (101,851) (5,195,007)
Forfeitures (21,532) (7,486) (10,409) (8,322) (8,071) (55,820)
Transfers 1,885,040 (944,969) 1,821,614 (2,662,737) (98,948)
Participant loan distr (234,159) (56,701) (80,509) (134,997) 506,366
Participant loan repay 177,778 46,229 59,166 65,970 27,264 (376,407)
Fees and expenses (201,673) (7,915) (78,705) (9,768) (298,061)
Balance at August 31, $37,492,725 $11,408,406 $16,523,866 $18,359,672 $748,524 $68,858 $1,184,790 $85,786,841
Contributions:
Company 674,939 171,615 237,961 179,485 111,318 1,375,318
Participant 2,052,103 533,306 797,360 450,790 281,907 4,115,466
Interest income 396,964 371,945 1,258,783 1,278,272 118 96,997 3,403,079
Dividend income 838,492 26,946 1,389 866,827
Net appreciation (depreciation)
in fair value of in 3,119,120 765,499 1,338 (128,169) (12,141) 3,745,647
Distributions (1,176,551) (251,680) (381,763) (432,560) (48,647) (20,641) (2,311,842)
Forfeitures (18,542) (9,338) (10,539) (7,971) (6,166) (52,556)
Transfers 1,101,117 (1,659,447) 897,262 (251,128) (87,804)
Participant loan distr (217,524) (37,941) (60,166) (93,436) 409,067
Participant loan repay 197,346 40,867 68,650 65,262 27,064 (399,189)
Fees and expenses (232,341) (7,097) (96,020) (3,266) 105 (338,619)
Balance at August 31, $44,227,848 $10,560,636 $20,000,893 $19,546,458 $924,973 $58,224 $1,271,129 $96,590,161
<FN>
The accompanying notes are an integral part of these financial statements.
</TABLE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies:
Contributions:
Contributions from participants are recorded on an accrual basis and are
deposited directly in the appropriate fund on a bi-weekly basis. Company
contributions are accrued on the basis of participants' contributions and
are made quarterly.
Investments Valuation:
Investments in securities (U.S. treasury bonds and notes, corporate bond
and bond investment funds, convertible preferred stock and common stocks)
traded on a national securities exchange are valued at the last reported
sales price on the last business day of the Plan's year; securities in
collective short-term investment funds and money market funds are stated
at fair value as determined by the Trustee of such funds. The capital
preservation fund is valued at contract value.
Withdrawals, Transfers and Forfeitures:
Withdrawals of participant and employer contributions can be made subject
to certain specified restrictions and tax consequences. Participants may
elect to transfer all or part of their balance of funds to other funds as
the Plan allows on a quarterly basis. Transfers between the capital
preservation fund and the money market funds are prohibited as are
transfers of participant balances to the company stock fund. Amounts
forfeited by participants, as described in Note 2, are applied to reduce
amounts that the Company is required to contribute to the Plan.
Distributions:
In accordance with guidance issued by the American Institute of Certified
Public Accountants, the Plan changed its method of accounting for
distributions such that all amounts elected by participants to be
withdrawn from the Plan are no longer recorded as a liability in the
statement of assets available for plan benefits but are recorded when
paid. Prior to 1993 withdrawals and distributions were recorded in the
period such amounts were authorized to be paid to participants.
This treatment results in a difference between the Plan's form 5500 and
the financial statements. Benefit obligations existing at August 31, 1993
were $2,844,657.
Other:
Purchases and sales of securities are reflected on a trade-date basis.
Dividend income is recorded on the ex-dividend date. Income from other
investments are recorded as earned on an accrual basis.
<PAGE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS
The Plan presents, in the statements of changes in net assets available
for plan benefits, the net appreciation (depreciation) in fair value of
its investments which consists of realized gains or losses and the
unrealized appreciation (depreciation) on those investments.
Trustee fees and investment management fees were paid by the Plan in 1993
and 1992.
2. Plan Description:
The following brief description of the DEKALB Genetics Corporation Savings
and Investment Plan (the Plan) is provided for general information
purposes only. Participants should refer to the Plan document for more
complete information.
The Plan, which was established effective September 1, 1982, is a
contributory defined contribution plan covering substantially all
employees of the Company and its subsidiaries. The Plan is subject to the
provisions of the Employee Retirement Income Security Act of 1974.
All monies received by the Trustee of the Plan are invested at the
direction of the participants in accordance with the terms of the Trust
Agreement. Participant contributions (from 1% to 15% of base pay) are
invested in the equity fund, money market fund, fixed income fund, capital
preservation fund or Company common stock fund maintained by the Trustee.
Company contributions (50% matching of participant contributions from 1%
to 6% of base pay) are invested in the various funds in proportion to the
participants' investment in such funds. The Company may elect to
contribute an additional amount at the discretion of the Board of
Directors.
Contributions from participants are credited directly to their account in
each fund. Employee contributions are invested in multiples of 10%.
Transfers of account balances must be in whole percentages. Rollovers
from prior qualified plans are invested at the employee's discretion.
Company matching contributions and any discretionary Company matching
contributions are invested in the investment funds in the same proportions
as the participant's employee pre-tax contributions. A participant may
change his investment direction with respect to his current account and
future contributions no more than four times per year (March 1, June 1,
September 1 and December 1 of each year) by giving the Plan's
administrative committee written notice in the prescribed form. Changes
in investment direction of the current account balance will become
effective as of the first day in the next Plan quarter. Changes in
investment direction of future contributions become effective as of the
first payroll pay date in the next Plan quarter.
<PAGE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS, Continued
2. Plan Description, Continued:
There are currently five investment funds available to participants. These
five funds are described briefly below:
(a) Equity fund. The equity fund is a pooled fund invested primarily in
common stocks. There are no guarantees with respect to principal or
investment return.
(b) Money market fund. The money market fund is a pooled fund maintained
and managed by the Trustee that is invested in short term debt
securities such as commercial paper and certificates of deposit. There
are no guarantees with respect to principal or investment return.
(c) Fixed income fund. The fixed income fund is a pooled fund invested
primarily in corporate and government bonds of intermediate, (e.g.,
five to seven year) term. There are no guarantees with respect to
principal or investment return.
(d) Capital Preservation fund. The capital preservation fund is
underwritten by the Aetna Insurance Company. There are no guarantees
with respect to payment of income or principal. The investments in the
fund are valued at contract value.
(e) Company common stock fund. The Company common stock fund enables
participants to purchase DEKALB Genetics Corporation Class A Common
Stock. The per share purchase price equals the average of the per
share closing price of Class B Common Stock as quoted on the National
Association of Securities Dealers Automated Quotation System/National
Market System (NASDAQ/NMS) on the last ten (10) trading days prior to
the date of purchase. The Board of Directors has authorized up to
100,000 shares of Class A Common Stock as available for purchase by the
Plan. There are no guarantees with respect to principal or investment
return.
A sixth fund, the Pfizer stock fund, was created solely for the purpose of
holding common stock of Pfizer, Inc. received by the Plan through employee
rollover contributions. No additional contributions may be made to this
fund.
A seventh fund, the Participant loan fund, was created in 1992 for the
purpose of recording participant loans and related activity. Prior to 1992,
the Plan recorded participant loans made as distributions and participant
loan repayments as participant contributions. Interest on these loans is
accumulated at prime plus one percent, determined at the date the loan is
granted.<PAGE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS, Continued
2. Plan Description, Continued:
A participant is at all times fully vested in his employee contribution
account. His employer contribution account vests at the rate of 20% per
year. Termination of employment before the completion of five (5) years
of service will result in forfeitures from the employer contribution
account unless such termination is due to the participant's attainment of
age 65 or death or disability. Distributions from the Plan are paid in
cash as a lump sum; provided, however, that distributions from the Company
common stock fund may, at the participant's election, be received in
either whole shares of DEKALB Genetics Corporation Class A Common Stock or
cash.
If the Plan is terminated, the interests of all participants or their
beneficiaries shall be fully vested and nonforfeitable and participants
shall be entitled to a distribution of their accrual balances.
Participants may apply for a loan from the Plan. The loan is limited to
the lesser of (1) $50,000 or (2) the greater of (a) one half of the
participant's vested balance or (b) $10,000 or the amount of the vested
account balance if less than $10,000. The maximum permitted amount of a
loan shall be further reduced such that the amount of the loan (plus the
outstanding balance of all prior loans) shall not exceed 50% of the
Participant's vested accounts. Interest is charged at rates comparable to
those of lending institutions. Loan repayments are made by the
participant through bi-weekly payroll deductions.
3. Investments:
Individual investments (at fair value) representing five percent or more
of net assets available for plan benefits in 1993 and 1992 are summarized
as follows:
Description 1993 1992
Harris Bank Common
Stock Fund $ 9,306,215 $7,305,231
Harris Bank Collective
Short Term Investment Fund $12,755,980 13,357,309
Aetna Guaranteed
Investment Account $17,727,605 $18,953,044
<PAGE>
<PAGE>
DEKALB GENETICS CORPORATION SAVINGS AND INVESTMENT PLAN
NOTES TO FINANCIAL STATEMENTS, Continued
4. Net Appreciation (Depreciation) in Fair Value of Investments:
The Plan's investments (including investments bought and sold, as well as
held, during the year) appreciated in value $3,745,647 and $2,722,726 for
the years ended August 31, 1993 and 1992 respectively, summarized as
follows:
Description 1993 1992
DEKALB Genetics Corporation common stock $(128,169) $(112,986)
Common stocks 3,106,979 2,065,551
Corporate bond and bond investment funds 296,672 191,091
U.S. Treasury bonds and notes 470,165 579,070
$ 3,745,647 $2,722,726
5. Tax Status:
The Internal Revenue Service has issued a favorable determination letter
that (i) the Plan is qualified under Section 401(a) of the Code as in
effect prior to the Tax Reform Act of 1986 and (ii) the Trust maintained
under the Plan is tax-exempt under Section 501(a) of the Code. The
determinations of the Internal Revenue Service were conditioned upon the
Company's adoption of certain changes to the Plan, which the Company has
adopted in a timely manner.
<PAGE>
<PAGE>
SUPPLEMENTAL SCHEDULES
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings And Investment Plan
ITEM 27a - Schedule of Assets Held for Investment Purposes
August 31, 1993
NUMBER OF
SHARES OF MARKET
DESCRIPTION FACE VALUE VALUE COST
<S> <C> <C> <C>
DEKALB Genetics Corporation Comm 37,678 $923,111 $1,195,109
Common Stocks:
Alco Standard Corp. 13,000 593,125 432,189
AMP Inc. 24,200 1,566,950 1,198,849
Bausch & Lomb, Inc. 23,500 1,107,438 814,000
Becton Dickinson & Company 36,000 1,323,000 1,324,090
Boeing Company 24,900 986,662 881,849
Bristol Meyers & Co. Squibb C 14,600 819,425 859,618
Deluxe Corporation 16,000 588,000 596,800
Dover Corp. 27,000 1,414,125 938,630
Dun & Bradstreet 11,000 686,125 588,380
Exxon Corp. 21,500 1,405,562 1,057,114
General Signal Corporation 20,000 660,000 529,584
Genuine Parts Co. 33,700 1,255,325 873,519
Glaxo Holdings PLC 81,000 1,447,875 1,877,824
H & R Block, Inc. 30,000 1,207,500 1,094,335
Hartford Steam Boiler Inspect 14,000 684,250 769,413
Marsh & McLennan Co's Inc. 18,000 1,624,500 1,260,090
McCormick & Co., Inc. 16,000 354,000 328,672
Melville Corporation 29,000 1,363,000 1,401,105
Merck & Co. Inc. 15,100 481,312 396,858
Pacific Telesis Group 15,200 841,700 663,650
Pfizer, Inc. 852 53,676 55,806
Phillip Morris Companies Inc. 26,000 1,267,500 1,253,420
Raytheon Company 21,000 1,330,300 871,936
Readers Digest Assn., Inc. 17,000 667,250 656,897
Royal Dutch Petroleum Co. N.Y 15,000 1,505,625 1,167,786
Schering-Plough Corp. 28,000 1,711,500 1,317,832
State Street Boston Corporati 20,000 680,000 633,480
Tambrands, Inc. 18,500 897,250 858,662
Union Camp Corp. 34,000 1,525,750 1,371,059
Washington Post 3,000 661,500 615,124
Whitman Corporation 40,000 600,000 581,600
Woolworth Corp. 23,000 592,250 683,540
Harris Bank Common Stock Fund 38,840 9,306,215 5,991,172
Harris Bank Special Capital F 6,725 612,242 346,180
Harris Special Capital Liquid 20,531 3,947 2,965
Harris Bank Convertible Funds 2,641 1,014,373 887,402
Harris Bank Convertible Liqui 3,573 1,213
Total Common Stock $42,840,465 $35,181,430
</TABLE>
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings And Investment Plan
ITEM 27a - Schedule of Assets Held for Investment Purposes, Continued
August 31, 1993
NUMBER OF
SHARES OF MARKET
DESCRIPTION FACE VALUE VALUE COST
<S> <C> <C> <C>
Corporate Bond and Bond Investment Funds:
Harris Bank Collective Investment Funds -
Enhanced Liquidity Fund 3,896 $1,292,904 $1,291,566
Marketable Bond Fund 7,949 7,015,421 6,119,213
Total Bond Investment Funds 8,308,325 7,410,779
U.S. Treasury Bonds and Notes:
U.S. Treasury note, 8.00% due 500,000 519,375 483,969
U.S. Treasury note, 8.625% du 300,000 319,827 300,844
U.S. Treasury note, 7.25% due 600,000 652,596 546,720
U.S. Treasury note, 7.5% due 500,000 539,375 509,141
U.S. Treasury note, 8.625% du 650,000 745,875 666,655
U.S. Treasury note, 8.875% du 300,000 348,702 303,000
U.S. Treasury note, 9.00% due 400,000 471,376 405,656
U.S. Treasury note, 9.25% due 200,000 239,062 199,312
U.S. Treasury note, 7.125% du 500,000 551,720 502,344
U.S. Treasury note, 8.875% du 200,000 237,812 195,000
U.S. Treasury note, 7.875% du 500,000 575,390 509,375
U.S. Treasury note, 8.50% due 750,000 890,273 852,187
U.S. Treasury note, 7.75% due 1,000,000 1,154,220 1,032,344
U.S. Treasury note, 7.5% due 1,000,000 1,145,310 1,002,813
U.S. Treasury bond, 12.625% d 100,000 114,500 100,875
U.S. Treasury bond, 8.50% due 400,000 413,812 388,750
U.S. Treasury bond, 7.875% du 600,000 633,750 561,156
U.S. Treasury bond, 10.75% du 600,000 831,186 669,750
U.S. Treasury bond, 11.125% d 100,000 142,562 95,625
U.S. Treasury bond, 8.25% due 400,000 464,564 370,750
U.S. Treasury bond, 9.375% du 700,000 928,921 710,622
U.S. Treasury bond, 8.375% du 500,000 599,920 530,625
Total U.S. Treasury Bonds and Notes 12,520,128 10,937,513
Harris Bank Collective
Short-Term Investment Fund 12,755,980 12,755,980
Aetna Guaranteed Investment Account 17,727,605 17,727,605
Participant Loans, 7% to 12.5% 1,255,046 1,255,046
$96,330,660 $86,463,462
</TABLE>
<TABLE>
<CAPTION>
DEKALB Genetics Corporation Savings And Investment Plan
ITEM 27d - Schedule of Reportable Transactions
August 31, 1993
IDENTITY OF PARTY AND CURRENT NET GAIN
DESCRIPTION OF ASSET COST OF ASSET VALUE OF ASSET OR (LOSS)
<S> <C> <C> <C>
Harris Trust & Savings Bank
Collective Short-Term Investment Fund
346 Purchases $23,421,369 $23,421,369 $0
219 Sales 22,846,824 22,846,824 0
Harris Bank Collective Investment
Fund-Marketable Bond Fund
48 Purchases $4,362,128 $4,362,128 $0
1 Sale 918,776 902,252 16,524
</TABLE>
